#Switzerland #Investment - Novartis AG (NVS) Agrees $12 Billion Biotech Deal for Avidity: Bloomberg Television

27 October 2025

Novartis (NVS) agreed to buy biotechnology company Avidity in a deal valued at $12 billion, making it the Swiss drugmaker’s biggest acquisition in more than a decade and adding several potential blockbuster treatments as generic competition looms for its current top-sellers.

Sam Fazeli of Bloomberg Intelligence has more.

AI-Powered Stock Picking

danelfin - smart investing made easy

Trade Idea of the Week: ROAD (Construction Partners)

Construction Partners is a BUY for Danelfin AI. We highlight every week a stock with a high win rate track record.